ArticleClinical transplantation2026
The Use of Pediatric Donors in Pancreas Transplantation.
Article in Clinical transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe use of pediatric donors in simultaneous pancreas-kidney transplantation (SPKT) and solitary pancreas transplantation is not universally accepted
methodsSingle center retrospective review of 310 consecutive SPKTs and 50 solitary pancreas transplants performed from 11/1/01 to 1/1/25. All patients received depleting antibody induction with tacrolimus/mycophenolate/prednisone maintenance therapy. Pediatric donors were defined as age <18 years.
resultsIn the SPKT group, 72 patients (23.2%) received organs from donors <18 years (mean 13.9 years), 215 from donors 18-40 years (mean 26.4 years), and 23 from donors >40 years of age (mean 47.4 years). Rates of early pancreas thrombosis were 5.6%, 6.5%, and 4.3% (p = 0.51), according to increasing donor age category. One-year death-censored pancreas and kidney graft survival rates (GSRs) were 93.0%, 92.0%, and 90.5%; and 98.6%, 99.1%, and 95.5%, respectively (both p = NS). Four-year death-censored pancreas GSRs were 87.9%, 78.7%, and 90.5%, respectively (p = 0.08). There were 11 pediatric donors ≤40 kg body weight (smallest 28 kg). One-year patient, pancreas, and kidney GSRs were 100% and 4-year patient and pancreas GSRs were 100% (kidney GSR 90%). There were no technical pancreas or kidney graft losses in the ≤40 kg donor group, and pancreas graft survival beyond 18 years has occurred. In 11 patients receiving solitary pancreas transplants from pediatric donors, there were no cases of early thrombosis.
conclusionsDespite concerns related to small caliber vessels and donor/recipient size mismatch, pediatric donors are associated with excellent mid-term outcomes in SPKT recipients and may not represent a contraindication to pancreas utilization in solitary pancreas transplantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.